Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

IDEAYA Biosciences (IDYA) EBT Margin (2020 - 2025)

IDEAYA Biosciences' EBT Margin history spans 6 years, with the latest figure at 869.53% for Q4 2025.

  • For Q4 2025, EBT Margin rose 118959.0% year-over-year to 869.53%; the TTM value through Dec 2025 reached 1464.81%, up 320626.0%, while the annual FY2025 figure was 72.84%, 459823.0% up from the prior year.
  • EBT Margin for Q4 2025 was 869.53% at IDEAYA Biosciences, up from 2059.11% in the prior quarter.
  • Across five years, EBT Margin topped out at 2.22% in Q3 2022 and bottomed at 2059.11% in Q4 2024.
  • The 5-year median for EBT Margin is 400.81% (2022), against an average of 559.89%.
  • The largest annual shift saw EBT Margin crashed -99062bps in 2024 before it soared 118959bps in 2025.
  • A 5-year view of EBT Margin shows it stood at 620.16% in 2021, then decreased by -6bps to 657.46% in 2022, then crashed by -63bps to 1068.49% in 2023, then plummeted by -93bps to 2059.11% in 2024, then skyrocketed by 58bps to 869.53% in 2025.
  • Per Business Quant, the three most recent readings for IDYA's EBT Margin are 869.53% (Q4 2025), 2059.11% (Q4 2024), and 1068.49% (Q4 2023).